The Public M&A team advised GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) in its definitive agreement to be acquired by a group of buyers led by Fall Line Capital, LLC in an all-cash transaction valuing the company at approximately $45.5 million.
GreenLight Biosciences is a public benefit corporation that aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. The company’s RNA platform allows them to research, design, and manufacture for human, animal, and plant health. In human health, this includes messenger RNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops.
The Goodwin team was led by Jeff Letalien and Kirkie Maswoswe and included Wei Xu, Jessica Park and Swetha Gopalakrishnan (Public M&A), with assistance from Folake Ayoola, Justin Anslow, and Della Fok (Capital Markets), James Barri and Reid Bagwell (Debt), Crescent Moran Chasteen, Andre Amorim, and James Oh (Executive Compensation and Benefits), Simone Waterbury and Charlie Stewart (Antitrust), Morgan Mordecai (Litigation), James Riley and Kevin Liu (Intellectual Property), Roger Cohen and Heath Ingram (Healthcare), and Alex Apostolopoulos and Erika Pey (Tax).
For additional details on the agreement, please read the press release.